Patient with Resistant Hypertension
A 68-year-old, Caucasian male was referred by his family physician for assessment of uncontrolled arterial hypertension. He is treated with three antihypertensive drugs. 24-h ambulatory blood pressure monitoring (ABPM) was performed, and the final diagnosis was true resistant hypertension.
The definition of resistant hypertension is based on office blood pressure (BP) measurements. ABPM is mandatory in resistant hypertensive patients to define true and white-coat resistant hypertension, as the latter group has a better prognosis.
KeywordsResistant hypertension 24-h ambulatory blood pressure monitoring Cardiovascular risk High blood pressure Spironolactone
- 1.Williams B, Mancia G, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;39(33):3021–104.Google Scholar
- 2.Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:2199–269.CrossRefGoogle Scholar
- 3.Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.CrossRefGoogle Scholar
- 8.Segura J, Ruilope LM. Resistant hypertension. In: Lerma EV, Rosner MH, Perazella MA, editors. Current diagnosis & treatment: nephrology & hypertension. 2nd ed. New York: McGraw-Hill Education; 2018.Google Scholar
- 13.Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.CrossRefGoogle Scholar